Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095200 | 0.84 | KCNH2 (0.46) | CCR1F2RTERTALDH1A1KCNH2 | |
| SCHEMBL12664449 | 0.83 | KCNH2 (0.45) | CCR1TERTALDH1A1KCNH2 | |
| SCHEMBL7092724 | 0.81 | KCNH2 (0.56) | CCR1F2RKCNH2 | |
| SCHEMBL7685865 | 0.81 | F2R (0.37) | F2RPARP1KCNH2CXCR4CHRNB2 | |
| SCHEMBL660572 | 0.81 | PARP1 (0.39) | F2RPARP1KCNH2CXCR4CHRNB2 | |
| SCHEMBL6605431 | 0.80 | CCR4 (0.36) | CCR1TERTALDH1A1 | |
| SCHEMBL945430 | 0.79 | CCR1 (0.40) | CCR1F2RTERTALDH1A1 | |
| SCHEMBL22354808 | 0.79 | CCR1 (0.40) | CCR1TERTALDH1A1 | |
| SCHEMBL29951735 | 0.79 | CCR1 (0.40) | CCR1TERTALDH1A1 | |
| SCHEMBL6984612 | 0.79 | CCR1 (0.40) | CCR1TERTALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367891-B | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | UNIV SOUTH CENTRAL NATIONALITI | 2010-09-08 | — | — | CN | claimed |
| CN-101367891-A | Nitrogen-nitrogen-oxygen nickel complex catalytic system for addition polymerisation of norbornene and its derivant, preparation method and uses thereof | SOUTH CENTRAL UNIVERSITY FOR N (CN) | 2009-02-18 | — | — | CN | claimed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-111285873-A | RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2641910-B1 | CHIRAL SPIRO-PYRIDYLAMIDOPHOSPHINE LIGAND COMPOUND, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF | ZHEJIANG JIUZHOU PHARMA SCIENCE & TECH CO LTD (CN) | 2017-06-28 | — | — | EP | disclosed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | disclosed |
| CN-1098263-C | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2003-01-08 | — | — | CN | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| CN-1242772-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2000-01-26 | — | — | CN | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
| US-5506227-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-04-09 | — | — | US | disclosed |
| EP-0639181-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-02-22 | — | — | EP | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| US-4267318-A | 1-(Diarylmethyl)-4-piperidinamine and derivatives thereof | G. D. SEARLE & CO. (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | CCR1 3724/4885F2R 3839/4885PARP1 386/4885 |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CCR1 2036/4885F2R 1849/4885PARP1 3808/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | CCR1 1981/4885F2R 285/4885PARP1 1083/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | CCR1 447/4885F2R 334/4885PARP1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.